dm+d

Unassigned

New Medicines

Social phobia (also known as social anxiety disorder)

Information

New molecular entity
VistaGen Therapeutics
VistaGen Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A neuroactive steroid which targets chemosensory receptors in the nose (and is directly connected to the hypothalamus), which then inhibit nerve circuits involved in the behavioral and physiological effects of anxiety.[3]
Social anxiety disorder is one of the most common anxiety disorders. Estimates of lifetime prevalence vary but have been as high as 12% [4].
Social phobia (also known as social anxiety disorder)
Intranasal